{
    "nct_id": "NCT03774472",
    "official_title": "Phase I/II Safety and Efficacy Study of Autophagy Inhibition With Hydroxychloroquine to Augment the Antiproliferative and Biological Effects of Pre-Operative Palbociclib Plus Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer",
    "inclusion_criteria": "* Signed written informed consent\n* Diagnosis of estrogen positive breast cancer, estrogen receptor-positive and HER2-negative by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) criteria\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Postmenopausal defined by: a. Age >= 55 years and 1 year or more of amenorrhea b. Age < 55 years and 1 year or more of amenorrhea with luteinizing hormone (LH) and/or follicle stimulating hormone (FSH) levels in the postmenopausal range c. Age < 55 with prior hysterectomy but intact ovaries with LH and/or FSH levels in the postmenopausal range d. Chemotherapy or medically induced ovarian suppression with 1 year or more of amenorrhea and with LH and/or FSH levels in the postmenopausal range e. Status after bilateral oophorectomy (>= 28 days prior to first study treatment)\n* Absolute neutrophil count (ANC) >= 1500 cells/ul\n* Platelet count >= 100,000/ul\n* Serum creatinine concentration < 1.5 x upper limit of normal (ULN)\n* Bilirubin level < 1.5 x ULN\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x ULN\n* Alkaline phosphatase =< 2.5 ULN\n* Metastatic cohorts (Phase I): Diagnosis of stage IV estrogen positive breast cancer, estrogen receptor-positive and HER2-negative by ASCO/CAP criteria\n* Metastatic cohorts (Phase I): Must be a candidate for treatment with CDK4/6 inhibitor and hormonal therapy with an aromatase inhibitor as standard of care\n* Metastatic cohorts (Phase I): No prior exposure to CDK 4/6 inhibitors\n* Neoadjuvant cohorts (Phase II): Diagnosis of stage I-III estrogen positive breast cancer, estrogen receptor-positive and HER2-negative by ASCO/CAP criteria. If stage I, clinical tumor size must be >= 1.5 cm\n* Neoadjuvant cohorts (Phase II): Baseline tumor Ki67 > 5%\n* Neoadjuvant cohorts (Phase II): Surgical candidate and appropriate for pre-operative endocrine therapy\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior exposure to CDK 4/6 inhibitor therapy\n* History of retinal disease or active visual disturbances (normal baseline study-specified retinal exam required)\n* Acute illness, including infections requiring medical therapy, known bleeding diathesis or need for anticoagulation\n* Treatment with any of the following medications within 4 weeks before the baseline diagnostic biopsy is taken: a. Oral estrogens, including hormone replacement therapy (but prior depot estrogen use not allowed). b. Investigational agents (or 5 half-lives, whichever is longer)\n* Required concomitant use of any drug that is a strong CYP3A inhibitor or inducer\n* Psychological, familial, sociological or geographical conditions that do not permit compliance with the study protocol\n* Life expectancy of less than 6 months\n* Pregnancy, lactation or planning to be pregnant.\n* Neo-adjuvant cohorts (Phase II): Prior therapy for breast cancer (medical, surgical or radiation therapy)\n* Neo-adjuvant cohorts (Phase II): Clinical T4 disease\n* Neo-adjuvant cohorts (Phase II): Inoperable or metastatic breast cancer based on standard evaluation",
    "miscellaneous_criteria": ""
}